Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Cambridge Epigenetix has raised $88.0M in total funding. The most recent round was Series D. The last funding was announced in November 2021.
Cambridge Epigenetix's investors include Temasek, Sequoia Capital, Third Point Ventures, Google Ventures, Ahren Innovation Capital.
Cambridge Epigenetix is headquartered in Cambridge, United Kingdom.
Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Cambridge Epigenetix is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cambridge Epigenetix — Funding & Investors." VCBacked, November 2, 2021, https://www.vcbacked.co/company/cambridge-epigenetix. Accessed November 12, 2026.
VCBacked. (2021). Cambridge Epigenetix — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/cambridge-epigenetix
{{cite web |title=Cambridge Epigenetix — Funding & Investors |url=https://www.vcbacked.co/company/cambridge-epigenetix |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Cambridge Epigenetix? Request a listing update